CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Application of lipid nanovesicle drug delivery system in cancer immunotherapy.
Application of lipid nanovesicle drug delivery system in cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗已逐渐成为最有前景的抗肿瘤疗法。除传统的抗PD-1/PD-L1治疗、抗CTLA-4治疗、CAR-T 治疗等,免疫治疗还可通过刺激免疫细胞成熟或抑制负性免疫细胞、调节肿瘤免疫微环境以及癌症疫苗等方式诱导。脂质纳米囊泡药物递送系统包括脂质体、细胞膜囊泡、细菌外膜囊泡、细胞外囊泡和杂交囊泡。脂质纳米囊泡既可作为癌症免疫治疗的功能性囊泡,也可作为药物载体将免疫治疗药物递送至肿瘤部位以用于癌症免疫治疗。在此,我们综述了五类脂质纳米囊泡在癌症免疫治疗中的最新进展,并评估了各类脂质纳米囊泡的临床应用前景,希望为未来的临床转化提供有价值的信息。
Immunotherapy has gradually emerged as the most promising anticancer therapy.
In addition to conventional anti-PD-1/PD-L1 therapy, anti-CTLA-4 therapy, CAR-T therapy, etc. , immunotherapy can also be induced by stimulating the maturation of immune cells or inhibiting negative immune cells, regulating the tumor immune microenvironment and cancer vaccines.
Lipid nanovesicle drug delivery system includes liposomes, cell membrane vesicles, bacterial outer membrane vesicles, extracellular vesicles and hybrid vesicles. Lipid nanovesicles can be used as functional vesicles for cancer immunotherapy, and can also be used as drug carriers to deliver immunotherapy drugs to the tumor site for cancer immunotherapy.
Here, we review recent advances in five kinds of lipid nanovesicles in cancer immunotherapy and assess the clinical application prospects of various lipid nanovesicles, hoping to provide valuable information for clinical translation in the future.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。